Clinical trials in cancer screening, prevention and early diagnosis (SPED): a systematic mapping review.
Cancer
Early detection of cancer
Prevention
Screening
Systematic mapping
Trials
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
04 Sep 2023
04 Sep 2023
Historique:
received:
14
12
2022
accepted:
14
08
2023
medline:
6
9
2023
pubmed:
5
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Global annual cancer incidence is forecast to rise to 27.5 M by 2040, a 62% increase from 2018. For most cancers, prevention and early detection are the most effective ways of reducing mortality. This study maps trials in cancer screening, prevention, and early diagnosis (SPED) to identify areas of unmet need and highlight research priorities. A systematic mapping review was conducted to evaluate all clinical trials focused on cancer SPED, irrespective of tumour type. The National Cancer Research Institute (NCRI) portfolio, EMBASE, PubMed and Medline were searched for relevant papers published between 01/01/2007 and 01/04/2020. References were exported into Covidence software and double-screened. Data were extracted and mapped according to tumour site, geographical location, and intervention type. One hundred seventeen thousand seven hundred one abstracts were screened, 5157 full texts reviewed, and 2888 studies included. 1184 (52%) trials focussed on screening, 554 (24%) prevention, 442 (20%) early diagnosis, and 85 (4%) a combination. Colorectal, breast, and cervical cancer comprised 61% of all studies compared with 6.4% in lung and 1.8% in liver cancer. The latter two are responsible for 26.3% of global cancer deaths compared with 19.3% for the former three. Number of studies varied markedly according to geographical location; 88% were based in North America, Europe, or Asia. This study shows clear disparities in the volume of research conducted across different tumour types and according to geographical location. These findings will help drive future research effort so that resources can be directed towards major challenges in cancer SPED.
Sections du résumé
BACKGROUND
BACKGROUND
Global annual cancer incidence is forecast to rise to 27.5 M by 2040, a 62% increase from 2018. For most cancers, prevention and early detection are the most effective ways of reducing mortality. This study maps trials in cancer screening, prevention, and early diagnosis (SPED) to identify areas of unmet need and highlight research priorities.
METHODS
METHODS
A systematic mapping review was conducted to evaluate all clinical trials focused on cancer SPED, irrespective of tumour type. The National Cancer Research Institute (NCRI) portfolio, EMBASE, PubMed and Medline were searched for relevant papers published between 01/01/2007 and 01/04/2020. References were exported into Covidence software and double-screened. Data were extracted and mapped according to tumour site, geographical location, and intervention type.
RESULTS
RESULTS
One hundred seventeen thousand seven hundred one abstracts were screened, 5157 full texts reviewed, and 2888 studies included. 1184 (52%) trials focussed on screening, 554 (24%) prevention, 442 (20%) early diagnosis, and 85 (4%) a combination. Colorectal, breast, and cervical cancer comprised 61% of all studies compared with 6.4% in lung and 1.8% in liver cancer. The latter two are responsible for 26.3% of global cancer deaths compared with 19.3% for the former three. Number of studies varied markedly according to geographical location; 88% were based in North America, Europe, or Asia.
CONCLUSIONS
CONCLUSIONS
This study shows clear disparities in the volume of research conducted across different tumour types and according to geographical location. These findings will help drive future research effort so that resources can be directed towards major challenges in cancer SPED.
Identifiants
pubmed: 37667231
doi: 10.1186/s12885-023-11300-8
pii: 10.1186/s12885-023-11300-8
pmc: PMC10476302
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
820Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
World Health Organisation. https://www.who.int/news-room/fact-sheets/detail/cancer 2021 [cited 2021 30/05/2021].
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
doi: 10.3322/caac.21492
pubmed: 30207593
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
Wild CP, Espina C, Bauld L, Bonanni B, Brenner H, Brown K, et al. Cancer prevention Europe. Mol Oncol. 2019;13(3):528–34.
doi: 10.1002/1878-0261.12455
pubmed: 30667152
pmcid: 6396376
Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118(8):1130–41.
doi: 10.1038/s41416-018-0029-6
pubmed: 29567982
pmcid: 5931106
Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tob Control. 2012;21(2):96–101.
doi: 10.1136/tobaccocontrol-2011-050294
pubmed: 22345230
Hait WN, Levine AJ. genomic complexity: a call to action. Sci Transl Med. 2014;6(255):255cm10.
Badrick E, Cresswell K, Ellis P, Crosbie P, Hall PS, O’Flynn H, et al. Top ten research priorities for detecting cancer early. The Lancet Public Health. 2019;4(11): e551.
Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91–108.
doi: 10.1111/j.1471-1842.2009.00848.x
pubmed: 19490148
James KL, Randall NP, Haddaway NR. A methodology for systematic mapping in environmental sciences. Environmental Evidence. 2016;5(1):7.
doi: 10.1186/s13750-016-0059-6
The Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf . 2020.
Begum M, Lewison G, Lawler M, Sullivan R. Mapping the European cancer research landscape: an evidence base for national and Pan-European research and funding. Eur J Cancer (Oxford, England : 1990). 2018;100:75–84.
Aggarwal A, Patel P, Lewison G, Ekzayez A, Coutts A, Fouad FM, et al. The profile of Non-Communicable Disease (NCD) research in the Middle East and North Africa (MENA) region: analyzing the NCD burden, research outputs and international research collaboration. PLoS ONE. 2020;15(4): e0232077.
doi: 10.1371/journal.pone.0232077
pubmed: 32339197
pmcid: 7185716
Aggarwal A, Lewison G, Idir S, Peters M, Aldige C, Boerckel W, et al. The State of lung cancer research: a global analysis. J Thorac Oncol. 2016;11(7):1040–50.
doi: 10.1016/j.jtho.2016.03.010
pubmed: 27013405
Cancer Research UK. Cancer Research UK Annual Report and Accounts 2019/2020. 2020.
National Cancer Institute. https://www.cancer.gov/about-nci/budget/fact-book/data/research-funding 2020.